Marques Borges, Gabriel Silva published the artcileNovel self-nanoemulsifying drug-delivery system enhances antileukemic properties of all-trans retinoic acid, Recommanded Product: N1,N2-Dibenzylethane-1,2-diamine, the publication is Nanomedicine (London, United Kingdom) (2020), 15(15), 1471-1486, database is CAplus and MEDLINE.
All-trans retinoic acid (ATRA) shows erratic oral bioavailability when administered orally against leukemia, which can be solved through its incorporation in self-nanoemulsifying drug-delivery systems (SEDDS). The SEDDS developed contained a hydrophobic ion pair between benzathine (BZT) and ATRA and was enriched with tocotrienols by the input of a palm oil tocotrienol rich fraction (TRF) in its composition SEDDS-TRF-ATRA-BZT allowed the formation of emulsions with nanometric size that retained ATRA within their core after dispersion. Pharmacokinetic parameters after oral administration of SEDDS-TRF-ATRA-BZT in mice were improved compared with what was seen for an ATRA solution Moreover, SEDDS-TRF-ATRA-BZT had improved activity against HL-60 cells compared with SEDDS without TRF. SEDDS-TRF-ATRA-BZT is a promising therapeutic choice over ATRA conventional medicine. SEDDS-TRF-ATRA-BZT after dispersion in ultrapure water produces nanoemulsions that have improved ATRA oral pharmacokinetics in Swiss male mice and improved its differentiation and cytotoxic properties against HL-60 cells.
Nanomedicine (London, United Kingdom) published new progress about 140-28-3. 140-28-3 belongs to catalysis-chemistry, auxiliary class Benzenes, name is N1,N2-Dibenzylethane-1,2-diamine, and the molecular formula is C16H20N2, Recommanded Product: N1,N2-Dibenzylethane-1,2-diamine.
Referemce:
https://courses.lumenlearning.com/boundless-chemistry/chapter/catalysis/,
Catalysis – Wikipedia